SCHEMBL7500864

SCHEMBL7500864

CCn1c(=O)oc2cc(Cl)c(NS(=O)(=O)c3cc(C)ccc3OC)cc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MAPK1 P28482 1/20 0.54
TSHR P16473 4/20 0.52
NPSR1 Q6W5P4 2/20 0.52
SMN1; SMN2 Q16637 5/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
HSD17B10 Q99714 1/20 0.51
USP2 O75604 1/20 0.47
THRB P10828 1/20 0.47
HPGD P15428 1/20 0.47
BRD4 O60885 2/20 0.46
LMNA P02545 3/20 0.44
HTT P42858 2/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7502554 0.91 ALDH1A1 (0.52) ALDH1A1MEN1KMT2ATSHRNPSR1
SCHEMBL7500569 0.87 KMT2A (0.59) ALDH1A1MEN1KMT2AMAPK1TSHR
SCHEMBL7502611 0.84 BRD4 (0.58) ALDH1A1MEN1KMT2ATSHRNPSR1
SCHEMBL7501872 0.84 ALDH1A1 (0.55) ALDH1A1MEN1KMT2AMAPK1TSHR
SCHEMBL7528355 0.82 ALDH1A1 (0.58) ALDH1A1MEN1KMT2AMAPK1TSHR
SCHEMBL7542434 0.80 ALDH1A1 (0.59) ALDH1A1MEN1KMT2AMAPK1TSHR
SCHEMBL7537329 0.80 ALDH1A1 (0.59) ALDH1A1MEN1KMT2AMAPK1TSHR
SCHEMBL7501770 0.78 TP53 (0.55) ALDH1A1MEN1KMT2ATSHRSMN1; SMN2
SCHEMBL7503590 0.77 TP53 (0.60) TSHRNPSR1SMN1; SMN2USP2BRD4
SCHEMBL7500575 0.77 MEN1 (0.59) ALDH1A1MEN1KMT2AMAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS INC (US) 2017-01-12 US disclosed
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS INC (US) 2017-01-12 US disclosed
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-8501953-B2 PKM2 modulators for use in the treatment of cancer AGIOS PHARMACEUTICALS, INC (US) 2013-08-06 US disclosed
US-8501953-B2 PKM2 modulators for use in the treatment of cancer AGIOS PHARMACEUTICALS, INC (US) 2013-08-06 US disclosed
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. 2012-05-17 US disclosed
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER PDK2, PDK1, PDK3 ALDH1A1 1326/4885MEN1 3231/4885KMT2A 429/4885
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 ALDH1A1 1390/4885MEN1 4239/4885KMT2A 848/4885
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 ALDH1A1 1390/4885MEN1 4239/4885KMT2A 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.